This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Sep;19(9):567.

doi: 10.1038/s41571-022-00673-7.

Liso-cel effective in R/R LBCL

Peter Sidaway¹

Affiliations

PMID: 35918608
DOI: 10.1038/s41571-022-00673-7

Comment

Liso-cel effective in R/R LBCL

Peter Sidaway. Nat Rev Clin Oncol. 2022 Sep.

. 2022 Sep;19(9):567.

doi: 10.1038/s41571-022-00673-7.

Author

Peter Sidaway¹

Affiliation

¹ Nature Reviews Clinical Oncology, . nrclinonc@springernature.com.

PMID: 35918608
DOI: 10.1038/s41571-022-00673-7

No abstract available

PubMed Disclaimer

Comment on

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI. Sehgal A, et al. Lancet Oncol. 2022 Aug;23(8):1066-1077. doi: 10.1016/S1470-2045(22)00339-4. Epub 2022 Jul 12. Lancet Oncol. 2022. PMID: 35839786 Clinical Trial.

References

Original article

1. Sehgal, A. et al. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00339-4 (2022) - DOI - PubMed

Related article

1. Kamdar, M. et al. Lancet https://doi.org/10.1016/S0140-6736(22)00662-6 (2022) - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions